Market Place
Sourcing Support
iTeos Reports Interim Analysis Of Belrestotug + Dostarlimab In NSCLC
14 Sep 2024 //
GLOBENEWSWIRE
Elevation Oncology Reports Q2 2024 Results And Achievements
06 Aug 2024 //
PR NEWSWIRE
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
09 Jul 2024 //
PR NEWSWIRE
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study
08 Jul 2024 //
GLOBENEWSWIRE
iTeos And GSK Initiate Phase 3 Study For Belrestotug And Dostarlimab In NSCLC
17 Jun 2024 //
GLOBENEWSWIRE
Jemperli Shows 100% No Evidence Of Disease In dMMR Rectal Cancer
03 Jun 2024 //
BUSINESSWIRE
Anaptys Gets $50M For More Jemperli Royalties From Sagard Deal
09 May 2024 //
GLOBENEWSWIRE
Positive RUBY phase III data show potential for Jemperli combinations
16 Mar 2024 //
BUSINESSWIRE
First Patient Dosed with LIXTE`s LB-100 and GSK`s Immunotherapy Dostarlimab-gxly
29 Jan 2024 //
GLOBENEWSWIRE
GSK`s cancer drug combination meets primary goal in late-stage trial
19 Dec 2023 //
PRESS RELEASE
GSK’s Jemperli plus chemotherapy approved as the first and only frontline immuno-oncology treatment in EU
11 Dec 2023 //
PRESS RELEASE
GSK`s cancer drug Jemperli meets overall survival goal in late-stage trial
30 Oct 2023 //
REUTERS
ESMO: Jemperli appears to show survival edge over Keytruda
21 Oct 2023 //
FIERCE PHARMA
GSK highlights new data in non-small cell lung cancer at ESMO Congress 2023
17 Oct 2023 //
PRESS RELEASE
GSK beats Merck to first PD-1 approval in newly diagnosed endometrial cancer
01 Aug 2023 //
FIERCE PHARMA
GSK`s Biologic Jemperli (dostarlimab) Receives Approval in the U.S.
31 Jul 2023 //
FDA
Italian AAV biotech closes $65M Series A; GSK`s Jemperli nabs priority review
06 Jun 2023 //
ENDPTS
EMA validates MAA for Jemperli plus chemotherapy for recurrent endometrial cancer
26 Apr 2023 //
PRESS RELEASE
GSK details PhIII data for Jemperli in frontline endometrial cancer
28 Mar 2023 //
ENDPTS
GSK`s Jemperli loses initial edge on Merck`s Keytruda
27 Mar 2023 //
FIERCE PHARMA
GSK`s unusual Jemperli plan wins FDA panel backing—with a twist
11 Feb 2023 //
FIERCE PHARMA
FDA grants regular approval for Jemperli for repair-deficient endometrial cancer
10 Feb 2023 //
PR NEWSWIRE
GSK`s Jemperli bags regular FDA approval for dMMR endometrial cancer
10 Feb 2023 //
FDA
FDA assembles adcomm to review GSK`s Jemperli trial plans in rectal cancer
08 Feb 2023 //
ENDPTS
Dostarlimab combination facilitates promising lung cancer survival
08 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
GSK`s PII trial of Jemperli plus chemotherapy shows positive results
08 Dec 2022 //
PRESS RELEASE
GSK’s Jemperli RUBY PIII trial met its primary endpoint for endometrial cancer
02 Dec 2022 //
PRESS RELEASE
GSK unveils Keytruda head-to-head NSCLC data
01 Dec 2022 //
FIERCEPHARMA
GSK moves PD-1 Jemperli to pivotal NSCLC trial
06 Oct 2022 //
FIERCEPHARMA
Rare biomarker leads to ‘unprecedented’ results in small rectal cancer study
05 Jun 2022 //
ENDPTS
GlaxoSmithKline`s Dostarlimab Receives Supplemental Approval in U.S.
28 Apr 2022 //
FDA
Endometrial Cancer Treatment Approved in Canada
24 Dec 2021 //
ETURBONEWS
GSK to present new data in oncology pipeline and portfolio at ESMO Congress 2021
11 Sep 2021 //
PHARMABIZ
GSK`s Biological Dostarlimab-Gxly Receives Approval In the US
18 Aug 2021 //
FDA
FDA Grants Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent
17 Aug 2021 //
GLOBENEWSWIRE
Glaxosmithkline`s Biological Dostarlimab-Gxly Receives Approval In US
22 Apr 2021 //
FDA
Evrysdi leads latest CHMP recommendations
01 Mar 2021 //
PHARMATIMES
Dostarlimab Provides Durable Antitumor Activity in Patients With Mismatch
20 Jan 2021 //
FIRSTWORDPHARMA
GSK presents positive efficacy data of dostarlimab in mismatch repair
18 Jan 2021 //
PRESS RELEASE
GSK posts middling data from PD-1 Tesaro buyout drug
24 Apr 2020 //
FIERCE BIOTECH
Barron exhorts GSK scientists to take `smart risks`
22 Jul 2019 //
FIERCE BIOTECH
GSK reports positive data from trial of endometrial cancer drug
21 Mar 2019 //
REUTERS
